The universal flu vaccine developer saw its share price jump after the announcement of the possible cooperation.
BiondVax Pharmaceuticals Ltd. (TASE:BNDX) has reported this morning that the National Institutes of Health (NIH), an agency of the US Department of Health, is examining possible clinical cooperation with the company following the positive results from its second clinical trial for a universal flu vaccine for adults over 65.
Following the announcement to the TASE, the company's share price jumped 10.3% to NIS 1.33.
The company has been invited to a series of meetings with the NIT's Division of Microbiology and Infectious Diseases (DMID) and the US Army's Authority for Advanced Biomedical R&D.
Published by Globes, Israel business news - www.globes-online.com - on May 2, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012